Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients

Keisuke Masuyama, Minoru Goto, Sachio Takeno, Nobuo Ohta, Mitsuhiro Okano, Atsushi Kamijo, Motohiko Suzuki, Tetsuya Terada, Daiju Sakurai, Shigetoshi Horiguchi, Kohei Honda, Shoji Matsune, Takechiyo Yamada, Masafumi Sakashita, Atsushi Yuta, Takashi Fuchiwaki, Ikuyo Miyanohara, Takeo Nakayama, Yoshitaka Okamoto, Shigeharu Fujieda

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: Sublingual immunotherapy (SLIT) appears to offer practical advantages for the treatment of allergic rhinitis (AR). Based on a review of the scientific literature, we present recommendations as guiding principles to administer SLIT safely. Methods: Clinical questions concerning SLIT were prepared. Literature published between January 2003 and December 2012 was searched from PubMed, the Cochrane Library, and Japana Centra Revuo Medicina. Qualified studies were analyzed and the results were evaluated, consolidated, and codified. We answered 17 clinical questions and, based on this, presented evidence-based recommendations. Results: Sublingual immunotherapy improved symptoms (e.g., quality of life [QOL]) and reduced medication scores in seasonal AR and perennial AR. Most SLIT-induced adverse effects were local oral reactions, although systemic adverse effects such as gastrointestinal symptoms, urticaria, and asthma are occasionally reported. There have been no reports of lethal anaphylactic reactions by SLIT. When SLIT is continued for 3-years, its effect persists long after discontinuation. Conclusion: A correct diagnosis of AR and sufficient informed consent from patients are required before initiating SLIT. Sublingual immunotherapy should be continued for 3 years or longer. The initial administration of SLIT during the uptitration of an allergen vaccine and the general condition of patients are critical for the safe performance of SLIT.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalAuris Nasus Larynx
Volume43
Issue number1
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Sublingual Immunotherapy
Allergic Rhinitis
Rhinitis, Allergic, Perennial
Seasonal Allergic Rhinitis
Urticaria
Anaphylaxis
Informed Consent
PubMed
Allergens
Libraries

Keywords

  • Allergic rhinitis
  • Guideline
  • Subcutaneous immunotherapy
  • Sublingual immunotherapy

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery

Cite this

Masuyama, K., Goto, M., Takeno, S., Ohta, N., Okano, M., Kamijo, A., ... Fujieda, S. (2016). Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients. Auris Nasus Larynx, 43(1), 1-9. https://doi.org/10.1016/j.anl.2015.08.015

Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients. / Masuyama, Keisuke; Goto, Minoru; Takeno, Sachio; Ohta, Nobuo; Okano, Mitsuhiro; Kamijo, Atsushi; Suzuki, Motohiko; Terada, Tetsuya; Sakurai, Daiju; Horiguchi, Shigetoshi; Honda, Kohei; Matsune, Shoji; Yamada, Takechiyo; Sakashita, Masafumi; Yuta, Atsushi; Fuchiwaki, Takashi; Miyanohara, Ikuyo; Nakayama, Takeo; Okamoto, Yoshitaka; Fujieda, Shigeharu.

In: Auris Nasus Larynx, Vol. 43, No. 1, 01.02.2016, p. 1-9.

Research output: Contribution to journalArticle

Masuyama, K, Goto, M, Takeno, S, Ohta, N, Okano, M, Kamijo, A, Suzuki, M, Terada, T, Sakurai, D, Horiguchi, S, Honda, K, Matsune, S, Yamada, T, Sakashita, M, Yuta, A, Fuchiwaki, T, Miyanohara, I, Nakayama, T, Okamoto, Y & Fujieda, S 2016, 'Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients', Auris Nasus Larynx, vol. 43, no. 1, pp. 1-9. https://doi.org/10.1016/j.anl.2015.08.015
Masuyama, Keisuke ; Goto, Minoru ; Takeno, Sachio ; Ohta, Nobuo ; Okano, Mitsuhiro ; Kamijo, Atsushi ; Suzuki, Motohiko ; Terada, Tetsuya ; Sakurai, Daiju ; Horiguchi, Shigetoshi ; Honda, Kohei ; Matsune, Shoji ; Yamada, Takechiyo ; Sakashita, Masafumi ; Yuta, Atsushi ; Fuchiwaki, Takashi ; Miyanohara, Ikuyo ; Nakayama, Takeo ; Okamoto, Yoshitaka ; Fujieda, Shigeharu. / Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients. In: Auris Nasus Larynx. 2016 ; Vol. 43, No. 1. pp. 1-9.
@article{3e96ef755e1c45798a26e4cf1cee4532,
title = "Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients",
abstract = "Objective: Sublingual immunotherapy (SLIT) appears to offer practical advantages for the treatment of allergic rhinitis (AR). Based on a review of the scientific literature, we present recommendations as guiding principles to administer SLIT safely. Methods: Clinical questions concerning SLIT were prepared. Literature published between January 2003 and December 2012 was searched from PubMed, the Cochrane Library, and Japana Centra Revuo Medicina. Qualified studies were analyzed and the results were evaluated, consolidated, and codified. We answered 17 clinical questions and, based on this, presented evidence-based recommendations. Results: Sublingual immunotherapy improved symptoms (e.g., quality of life [QOL]) and reduced medication scores in seasonal AR and perennial AR. Most SLIT-induced adverse effects were local oral reactions, although systemic adverse effects such as gastrointestinal symptoms, urticaria, and asthma are occasionally reported. There have been no reports of lethal anaphylactic reactions by SLIT. When SLIT is continued for 3-years, its effect persists long after discontinuation. Conclusion: A correct diagnosis of AR and sufficient informed consent from patients are required before initiating SLIT. Sublingual immunotherapy should be continued for 3 years or longer. The initial administration of SLIT during the uptitration of an allergen vaccine and the general condition of patients are critical for the safe performance of SLIT.",
keywords = "Allergic rhinitis, Guideline, Subcutaneous immunotherapy, Sublingual immunotherapy",
author = "Keisuke Masuyama and Minoru Goto and Sachio Takeno and Nobuo Ohta and Mitsuhiro Okano and Atsushi Kamijo and Motohiko Suzuki and Tetsuya Terada and Daiju Sakurai and Shigetoshi Horiguchi and Kohei Honda and Shoji Matsune and Takechiyo Yamada and Masafumi Sakashita and Atsushi Yuta and Takashi Fuchiwaki and Ikuyo Miyanohara and Takeo Nakayama and Yoshitaka Okamoto and Shigeharu Fujieda",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.anl.2015.08.015",
language = "English",
volume = "43",
pages = "1--9",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients

AU - Masuyama, Keisuke

AU - Goto, Minoru

AU - Takeno, Sachio

AU - Ohta, Nobuo

AU - Okano, Mitsuhiro

AU - Kamijo, Atsushi

AU - Suzuki, Motohiko

AU - Terada, Tetsuya

AU - Sakurai, Daiju

AU - Horiguchi, Shigetoshi

AU - Honda, Kohei

AU - Matsune, Shoji

AU - Yamada, Takechiyo

AU - Sakashita, Masafumi

AU - Yuta, Atsushi

AU - Fuchiwaki, Takashi

AU - Miyanohara, Ikuyo

AU - Nakayama, Takeo

AU - Okamoto, Yoshitaka

AU - Fujieda, Shigeharu

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objective: Sublingual immunotherapy (SLIT) appears to offer practical advantages for the treatment of allergic rhinitis (AR). Based on a review of the scientific literature, we present recommendations as guiding principles to administer SLIT safely. Methods: Clinical questions concerning SLIT were prepared. Literature published between January 2003 and December 2012 was searched from PubMed, the Cochrane Library, and Japana Centra Revuo Medicina. Qualified studies were analyzed and the results were evaluated, consolidated, and codified. We answered 17 clinical questions and, based on this, presented evidence-based recommendations. Results: Sublingual immunotherapy improved symptoms (e.g., quality of life [QOL]) and reduced medication scores in seasonal AR and perennial AR. Most SLIT-induced adverse effects were local oral reactions, although systemic adverse effects such as gastrointestinal symptoms, urticaria, and asthma are occasionally reported. There have been no reports of lethal anaphylactic reactions by SLIT. When SLIT is continued for 3-years, its effect persists long after discontinuation. Conclusion: A correct diagnosis of AR and sufficient informed consent from patients are required before initiating SLIT. Sublingual immunotherapy should be continued for 3 years or longer. The initial administration of SLIT during the uptitration of an allergen vaccine and the general condition of patients are critical for the safe performance of SLIT.

AB - Objective: Sublingual immunotherapy (SLIT) appears to offer practical advantages for the treatment of allergic rhinitis (AR). Based on a review of the scientific literature, we present recommendations as guiding principles to administer SLIT safely. Methods: Clinical questions concerning SLIT were prepared. Literature published between January 2003 and December 2012 was searched from PubMed, the Cochrane Library, and Japana Centra Revuo Medicina. Qualified studies were analyzed and the results were evaluated, consolidated, and codified. We answered 17 clinical questions and, based on this, presented evidence-based recommendations. Results: Sublingual immunotherapy improved symptoms (e.g., quality of life [QOL]) and reduced medication scores in seasonal AR and perennial AR. Most SLIT-induced adverse effects were local oral reactions, although systemic adverse effects such as gastrointestinal symptoms, urticaria, and asthma are occasionally reported. There have been no reports of lethal anaphylactic reactions by SLIT. When SLIT is continued for 3-years, its effect persists long after discontinuation. Conclusion: A correct diagnosis of AR and sufficient informed consent from patients are required before initiating SLIT. Sublingual immunotherapy should be continued for 3 years or longer. The initial administration of SLIT during the uptitration of an allergen vaccine and the general condition of patients are critical for the safe performance of SLIT.

KW - Allergic rhinitis

KW - Guideline

KW - Subcutaneous immunotherapy

KW - Sublingual immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84958058886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958058886&partnerID=8YFLogxK

U2 - 10.1016/j.anl.2015.08.015

DO - 10.1016/j.anl.2015.08.015

M3 - Article

AN - SCOPUS:84958058886

VL - 43

SP - 1

EP - 9

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

IS - 1

ER -